X
[{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Begins Proof Of Concept Trial In PNH Patients With Oral Factor D Inhibitor, BCX9930","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Pluri"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eXIthera Announces Publication of EP-7041 Data Demonstrating Safe Antithrombotic Activity in ECMO","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"eXIthera Pharmaceutical"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros\u2019 OMS906 Data Presented at Complement-based Drug Development Summit","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Omeros"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial for Treatment of Complement Dysregulation Diseases in Singapore","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Hatteras Venture","pharmaFlowCategory":"D","amount":"$16.6 million","upfrontCash":"Undisclosed","newsHeadline":"Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Veralox Therapeutics"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for Paroxysmal Nocturnal Hemoglobinuria (PNH)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Disc medicine"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Seeks DCGI Approval for Novel Oral Pill to Treat Anaemia in Kidney Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Zydus Lifesciences"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovelMed's Complement Alternative Pathway Specific Anti-Bb Antibody (NM8074) for Rare Diseases Achieves a Major Milestone","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"NovelMed Therapeutics"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Reports Positive Top-Line CAN106 Phase 1 Data Receives Approval to Treat Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Phase 1b\/2 Trial in China Results Suggest Complete Blockade of Complement Function CAN106 Safe and Well-Tolerated","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Disc medicine"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Keros Therapeutics"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge to Present CAN106 Phase 1 Data at the European Hematology Association 2022 Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Presents Positive Results from Phase 1 Clinical Study of DISC-0974 in Healthy Volunteers at the 2022 EHA Annual Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Disc medicine"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Doses First Patient with SCB-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Clover Biopharmaceuticals"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor\u2019s Broad Potential in Chronic Neutropenia (CN)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"X4 Pharmaceuticals"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillhurst Biopharmaceuticals Announces Completion Of Last Patient Last Visit In Phase 1 Clinical Trial Of HBI-002","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hillhurst Biopharmaceuticals"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Sirnaomics"},{"orgOrder":0,"company":"Velico Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Velico Medical Begins Clinical Trial on Spray Dried Plasma","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Velico Medical"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Magenta Therapeutics and Bluebird Bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta\u2019s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Magenta Therapeutics"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hillhurst Biopharmaceuticals Receives $3 Million in NIH SBIR Funding for Phase 2a Clinical Study in Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hillhurst Biopharmaceuticals"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The funding will be used by the company through a Phase 2a clinical study of HBI-002, an oral low dose carbon monoxide therapeutic candidate in patients with sickle cell disease (SCD).
Lead Product(s):
Carbon Monoxide
Therapeutic Area: Hematology
Product Name: HBI-002
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
National Heart, Lung, and Blood Institute
Deal Size: $3.0 million
Upfront Cash: Undisclosed
Deal Type: Funding
September 20, 2023
Details:
FrontlineODP(OnDemandPlasma) spray which is investigated in first in-human clinical trial Phase I safety trial for the prevention of trauma-induced coagulopathy.
Lead Product(s):
Plasma
Therapeutic Area: Hematology
Product Name: FrontlineODP
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 12, 2023
Details:
STP122G, Sirnaomics' leading RNAi drug candidate, is a siRNA that targets Factor XI and first participant Dosed in a Phase I clinical trial for prevention and treatment of stroke after atrial fibrillation.
Lead Product(s):
STP122G
Therapeutic Area: Hematology
Product Name: STP122G
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 01, 2023
Hillhurst Biopharmaceuticals Announces Completion Of Last Patient Last Visit In Phase 1 Clinical Trial Of HBI-002
Details:
HBI-002, is an oral drug product candidate of low dose CO, with an administration route designed to enable chronic use in a home setting for patients suffering from sickle cell disease.
Lead Product(s):
Carbon Monoxide
Therapeutic Area: Hematology
Product Name: HBI-002
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 23, 2023
Details:
Results of the Phase 1b clinical trial suggested that X4P-001 (mavorixafor) could be the first oral treatment for CN disorders and has the potential to reduce or replace injectable G-CSF, the current standard of care.
Lead Product(s):
Mavorixafor
Therapeutic Area: Hematology
Product Name: X4P-001
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 27, 2022
Details:
In pre-clinical studies, SCB-219M has demonstrated an extended serum half-life and favorable pharmacokinetics /pharmacodynamics (PK/PD) profile that supports weekly dosing possibility of the drug.
Lead Product(s):
SCB-219M
Therapeutic Area: Hematology
Product Name: SCB-219M
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 14, 2022
Details:
Data demonstrated for DISC-0974 robust increases in serum iron and improvements in markers of erythropoiesis including statistically significant increases of hemoglobin at the highest dose.
Lead Product(s):
DISC-0974
Therapeutic Area: Hematology
Product Name: DISC-0974
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 10, 2022
Details:
KER-012 is designed to bind to and inhibit the signaling of TGF-ß ligands that suppress bone growth, including activin A and activin B. KER-012 is being developed for the treatment of PAH and for the treatment of disorders associated with bone loss.
Lead Product(s):
KER-012
Therapeutic Area: Hematology
Product Name: KER-012
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 18, 2022
Details:
Poster to highlight data on safety, tolerability, pharmacokinetics, and effects on hepcidin and measures of iron metabolism of DISC-0974, designed to suppress hepcidin production by inhibiting the hemojuvelin from phase 1 study in healthy volunteers.
Lead Product(s):
DISC-0974
Therapeutic Area: Hematology
Product Name: DISC-0974
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 16, 2022
Details:
CAN106 is a long-acting, recombinant human mAB that specifically binds to and neutralizes C5 in the complement system, C5 is a validated mechanism of action in numerous hematology, nephrology, and neurology diseases, for treatment of multiple complement-mediated disorders.
Lead Product(s):
CAN106
Therapeutic Area: Hematology
Product Name: CAN106
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 12, 2022